Trial Status:
Current Trial - Enrollment Complete
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.
Purpose:
Combo Therapy for Cystic Fibrosis homozygote genotype DeltaF508.
Sponsor:
Vertex Pharmaceuticals
Principal Investigator:
Cori Daines, MD
Contact Information:
Osmara Y. Molina de Rodriguez, MS
Cell: (520) 891-6767 or Office: (520) 626-3910
Link to Study:
Principal Investigator:
Research Area:
Clinical and Population Research